Hikma, a London-based generics maker, has agreed to buy parts of Xellia’s assets in the U.S., including the Danish drugmaker’s manufacturing facility in Cleveland. Hikma will pay $135 million in cash with an additional $50 million going to Xellia based on contingencies, the company said in a press release. The deal is subject to approval from the U.S. Federal Trade Commission. Under terms of the transaction, Hikma gets the Cleveland facility that features end-to-end capabilities to develop, manufacture, pack and distribute lyophilized vials and aseptically filled ready-to-use IV bag products.
Read the full article: Hikma, Expanding Injectables Capacity, Acquires Some of Xellia’s US Assets for up to $185M //
Source: https://www.fiercepharma.com/manufacturing/hikma-acquires-part-xellias-us-assets-185m-expanding-injectables-capacity